Current Heart Failure Reports

, Volume 7, Issue 1, pp 1–8

Galectin-3 in Cardiac Remodeling and Heart Failure

  • Rudolf A. de Boer
  • Lili Yu
  • Dirk J. van Veldhuisen
Article

DOI: 10.1007/s11897-010-0004-x

Cite this article as:
de Boer, R.A., Yu, L. & van Veldhuisen, D.J. Curr Heart Fail Rep (2010) 7: 1. doi:10.1007/s11897-010-0004-x

Abstract

Galectin-3 is a member of the galectin family, which consists of animal lectins that bind β-galactosides. Recently, a role for galectin-3 in the pathophysiology of heart failure has been suggested. It was observed that galectin-3 is specifically upregulated in decompensated heart failure compared with compensated heart failure in animal models of heart failure. This has been associated with activation of fibroblasts and macrophages, which are a hallmark of cardiac remodeling. Therefore, galectin-3 may be a culprit biomarker in heart failure. Initial clinical observations indicate that galectin-3 may be a useful biomarker for decompensated heart failure, with incremental value over well-used “pressure-dependent” biomarkers, such as B-type natriuretic peptide. Future studies should focus on galectin-3 biology to better address the usefulness of galectin-3 as a biomarker and probe the usefulness of anti-galectin-3 therapy in treating heart failure.

Keywords

Galectin 3 Heart failure Prognosis Fibrosis Macrophages Biomarkers Renin-angiotensin system 

Copyright information

© The Author(s) 2010

Authors and Affiliations

  • Rudolf A. de Boer
    • 1
  • Lili Yu
    • 1
  • Dirk J. van Veldhuisen
    • 1
  1. 1.Department of Cardiology, Division of Experimental CardiologyUniversity Medical Center GroningenGroningenThe Netherlands

Personalised recommendations